期刊
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
卷 38, 期 1, 页码 86-94出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/147323001003800110
关键词
CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENDOTHELIAL FUNCTION; ROSIGLITAZONE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-gamma (PPAR gamma) AGONIST; CORONARY FLOW VELOCITY RESERVE
资金
- Major National Basic Research Program of China [2006CB503802]
- Chinese National Natural Science Foundation [30730042, 30770873]
The aim of this study was to assess the effect of rosiglitazone on endothelial function of the coronary arteries and on plasma levels of inflammatory markers in diabetic patients with coronary artery disease (CAD). Fifty-six patients with type 2 diabetes and CAD were randomized to receive either rosiglitazone (4 mg/day) or a control for 12 weeks. The coronary flow velocity reserve (CFVR) was assessed using transthoracic Doppler echocardiography at baseline and after 12 weeks. After 12 weeks of rosiglitazone treatment, plasma levels of C-reactive protein were significantly decreased and the median CFVR was significantly increased compared with baseline levels and compared with the control group. These results suggest that, in addition to its beneficial metabolic effects, rosiglitazone, via its anti-inflammatory effects, may improve endothelial function of the coronary arteries in patients with diabetes and CAD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据